Weight-loss medicine eligibility on the NHS (UK)

A practical overview of who may be assessed for NHS weight-loss treatment, how access works, and why availability can vary by area. Information only — not personal medical advice.

If you are trying to understand whether you might qualify for weight-loss medicine on the NHS, the most important thing to know is that NHS access is based on a pathway, not just on a medicine existing.

In practice, this usually means assessment through an NHS weight-management service, with structured support alongside any medicine. Access may vary depending on the medicine, your clinical circumstances, and where you live.

Quick answer

• NHS weight-loss injections are not available to everyone on request. Access is usually based on BMI, weight-related health conditions, and service criteria.
• Semaglutide (Wegovy) is generally prescribed through a specialist weight-management service rather than routine GP prescribing.
• Tirzepatide (Mounjaro) is being introduced through a phased NHS rollout, including primary care for some patients with the highest clinical need.
• Access can vary by area because NHS delivery depends on local pathways, commissioning, and rollout stages.

How NHS access works

The NHS pathway is not simply about whether a medicine is licensed. It is about whether you meet the relevant criteria and whether there is an NHS service set up to assess and support you.

NHS England guidance makes clear that obesity medicines are intended to sit within broader care, including behavioural and clinical support. For tirzepatide in primary care, NHS England also states that people prescribed treatment should have access to wraparound care, including dietary and physical activity advice.

In broad terms, NHS access may happen through:

Specialist weight-management services

This is the established NHS route for medicines such as semaglutide (Wegovy). NICE recommends semaglutide for weight management only when it is used within a specialist weight-management service providing multidisciplinary management, alongside a reduced-calorie diet and increased physical activity.

Primary care / GP pathway

For tirzepatide (Mounjaro), NHS England has described a phased introduction, including primary care, starting with people who have the highest clinical need while services and workforce capability are built.

Semaglutide (Wegovy): who may be assessed

NICE recommends semaglutide for managing overweight or obesity in adults only if it is used for a maximum of 2 years, within a specialist weight-management service, and the person has at least 1 weight-related comorbidity plus:

• a BMI of at least 35 kg/m2, or
• a lower BMI threshold, usually reduced by 2.5 kg/m2, for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean ethnic backgrounds.

NHS England's patient-facing guidance also describes semaglutide access through specialist services and notes BMI bands where a person may be prescribed semaglutide if they have health problems related to their weight. It also says eligibility may differ depending on your local ICB and advises checking locally.

How long can semaglutide be prescribed on the NHS?

For obesity management, semaglutide is recommended for a maximum of 2 years within the specialist-service pathway.

Tirzepatide (Mounjaro): phased NHS rollout

Tirzepatide is being introduced differently. NHS England says its inclusion in the NHS obesity pathway requires new services and training, so NICE agreed to a funding variation to allow a phased introduction rather than immediate access for the full eligible population.

NHS England says that a cohort of around 220,000 patients is being prioritised over the first 3 years of a wider 12-year rollout.

That means eligibility on paper is not always the same as immediate real-world availability.

Tirzepatide via specialist services

NHS England states that from 23 March 2025, tirzepatide may be prescribed for weight management through specialist weight-management services for eligible adults living with obesity and weight-related health problems.

Tirzepatide via primary care / GP

NHS patient guidance says you may be eligible for tirzepatide from a GP if you have:

• a BMI of 40 or more, and
• at least 4 specified weight-related health conditions, including type 2 diabetes, high blood pressure, cardiovascular disease, dyslipidaemia, and obstructive sleep apnoea.

The NHS also notes that BMI thresholds may be lower for some ethnic groups where health risks rise at lower BMI.

Why NHS eligibility can vary by area

People often get confused because different local NHS organisations may explain access slightly differently. That does not necessarily mean the rules are contradictory.

The main reasons are:

1) Local NHS delivery arrangements

NHS England notes that access may differ depending on your Integrated Care Board (ICB) and local pathway setup. Your local NHS system may be at a different stage of implementation.

2) Phased implementation

For tirzepatide, NHS England has explicitly adopted a phased approach, starting with those at highest clinical risk while capacity builds.

3) Pathway requirements

NHS England's wraparound-care information emphasises that medicines should be delivered with behavioural and clinical support, not simply issued in isolation.

What to do if you are trying to work out your next step

If you are unsure where you stand, the most useful approach is to think in stages:

• First, understand the general NHS criteria and pathway.
• Then, check whether your local NHS area is offering assessment through a specialist service or phased primary-care route.
• If you are comparing private care instead, compare service model, follow-up, governance, and full cost, not just brand names or speed.

Useful next reads

• NHS vs private weight-management: what's the difference?
• How we evaluate providers
• Questions to ask a private provider

Important note

This page is for general information only. It does not determine whether you are eligible or whether a medicine is suitable for you. NHS pathways, availability, and local delivery arrangements can change, and treatment decisions should be made by the appropriate NHS service or another qualified healthcare professional.

Next reads

• MHRA-authorised weight-loss medicines (UK)
• Questions to ask any provider
• Typical private cost ranges (UK)

Next steps